+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications



Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications



Respiratory Medicine 147: 44-50



Delayed drug hypersensitivity to first-line anti-tuberculosis medication is a major challenge in tuberculosis treatment. This study was performed to investigate the efficacy/tolerability of desensitization therapy in treatment of first-line anti-tuberculosis medication hypersensitivity and the usefulness of immunologic evaluation therein. This study was conducted as a prospective, observational cohort study. Subjects who experienced hypersensitivity reactions, including maculopapular exanthema (MPE) and drug reaction with eosinophilia and systemic symptoms (DRESS), to first-line anti-tuberculosis medications (isoniazid [INH], ethambutol [EMB], rifampin [RFP], and pyrazinamide [PZA]) were enrolled. Patch, intradermal, lymphocyte transformation, and oral provocation tests were performed to determine culprit drugs, which were desensitized with rapid and graded challenge protocols. Breakthrough reactions (BTRs) during or after desensitization were assessed. In total, 31 desensitization treatments (INH, 8; EMB, 8; RFP, 11; PZA, 4) to 12 patients (8 with MPE and 4 with DRESS) were performed. The overall success rate of desensitization was 80.7%. All the study subjects except one completed the full course of anti-tuberculosis treatment. The overall BTR free rate was 64.5%. Sixteen (80%) treatments for MPE and four (36.4%) for DRESS were BTR free (P = 0.023). Drugs that were positive on any two of three immunologic studies showed significantly high BTR rates (P = 0.014), although this was not correlated with desensitization failure rate. Rapid desensitization therapy to multiple anti-tuberculosis medications for delayed drug hypersensitivity was safe and successful. Combination of multiple immunologic evaluations may predict BTR although it needs validation in larger studies.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066446780

Download citation: RISBibTeXText

PMID: 30704698

DOI: 10.1016/j.rmed.2018.12.017


Related references

Successful drug desensitization in patients with delayed-type allergic reactions to anti-tuberculosis drugs. International Journal of Infectious Diseases 68: 61-68, 2018

Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Safety 38(3): 253-269, 2015

Treatment outcomes and tolerability of the revised WHO anti-tuberculosis drug dosages for children. International Journal of Tuberculosis and Lung Disease 22(2): 151-157, 2017

The mechanisms of antigen recognition in delayed hypersensitivities: in comparison with tuberculin type and Jones-Mote type delayed hypersensitivities. Fukuoka Igaku Zasshi 70(10): 614-628, 1979

Two cases of successful efavirenz desensitization in patients with several anti-HIV drugs hypersensitivities. Giornale Italiano di Dermatologia E Venereologia 150(4): 476-478, 2016

Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: A case report and review of the literature. Medicine 95(46): E5347, 2017

Study on drug resitance of mycobacterium tuberculosis in different age group and time of anti-tuberculosis medications in Hubei province. Wuhan Daxue Xuebao (Yixue Ban) 25(4): 470-473, 2004

Drug desensitization in 17-year-old male with Mast Cell Activation Syndrome, pneumonia, and antibiotic hypersensitivities. Ame Case Reports 1: 7, 2018

THU0223The Novel CPLA2 Inhibitor AK106-001616 is a New Category of Anti-Inflammatory/Analgesic Drug Demonstrating Efficacy and Favorable Tolerability in the Treatment of Rheumatoid Arthritis. Annals of the Rheumatic Diseases 72(Suppl 3): A240.1-A240, 2013

Antianginal Efficacy and Tolerability of Ranolazine as an Add-on Drug to Concomitant Medications Primarily Metoprolol in Chronic Stable Angina Patients: A Prospective, Open-Label Study. Journal of Pharmacology and Pharmacotherapeutics 8(1): 21-27, 2017

Study of variations of intensity of delayed hypersensitivities to the PmKo lipopolysaccharide and to tuberculin, in function of the anatomoclinical development of tuberculosis. Revue de Tuberculose et de Pneumologie 24: 605-632, 1960

Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. European Respiratory Journal 38(3): 730-733, 2012

Efficacy and tolerability of cinitapride in the treatment of functional dyspepsia and delayed gastric emptying. Gastroenterologia Y Hepatologia 32(10): 669-676, 2010

Efficacy and tolerability of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug: A review. Clinical Drug Investigation 22(12): 799-818, 2002

Tolerability of anti-tuberculosis treatment and HIV serostatus. International Journal of Tuberculosis and Lung Disease 11(11): 1203-1209, 2007